2025 Europe Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report
Description
The 2025 Europe Antibody Drug Conjugates Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Antibody Drug Conjugates (ADC) contract manufacturing in Europe are Lonza Group, Recipharm AB, Sterling Pharma Solutions, and Catalent, Inc. These companies are noted for their advanced manufacturing capabilities, regulatory expertise, and strong presence in Europe, particularly in Germany, the UK, and Switzerland, which are key hubs for ADC development and production.
Lonza Group stands out with substantial investments in scalable manufacturing technologies and precision oncology partnerships, contributing to its leadership in Europe’s ADC market. Recipharm AB and Sterling focus on specialized contract development and manufacturing services, offering tailored ADC production solutions. Catalent, Inc. complements this by providing integrated supply chain solutions and advanced bioprocessing infrastructure. These companies benefit from Europe’s robust biopharmaceutical infrastructure and supportive regulatory environment, enabling growth amid rising demand for targeted cancer therapies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Drug Conjugates Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in Antibody Drug Conjugates (ADC) contract manufacturing in Europe are Lonza Group, Recipharm AB, Sterling Pharma Solutions, and Catalent, Inc. These companies are noted for their advanced manufacturing capabilities, regulatory expertise, and strong presence in Europe, particularly in Germany, the UK, and Switzerland, which are key hubs for ADC development and production.
Lonza Group stands out with substantial investments in scalable manufacturing technologies and precision oncology partnerships, contributing to its leadership in Europe’s ADC market. Recipharm AB and Sterling focus on specialized contract development and manufacturing services, offering tailored ADC production solutions. Catalent, Inc. complements this by providing integrated supply chain solutions and advanced bioprocessing infrastructure. These companies benefit from Europe’s robust biopharmaceutical infrastructure and supportive regulatory environment, enabling growth amid rising demand for targeted cancer therapies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
